PA
BBIO icon

Profund Advisors’s BridgeBio Pharma BBIO Stock Holding History

Profund Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Sell
19,929
-10,448
-34% -$732K 0.04% 269
2026
Q1 		$2.26M Sell
30,377
-1,553
-5% -$113K 0.08% 176
2025
Q4 		$2.44M Sell
31,930
-2,298
-7% -$151K 0.07% 172
2025
Q3 		$1.78M Sell
34,228
-7,774
-19% -$379K 0.06% 214
2025
Q2 		$1.81M Sell
42,002
-619
-1% -$22.5K 0.07% 200
2025
Q1 		$1.47M Sell
42,621
-6,470
-13% -$218K 0.06% 221
2024
Q4 		$1.35M Buy
49,091
+125
+0.3% +$3.23K 0.05% 250
2024
Q3 		$1.25M Sell
48,966
-2,063
-4% -$54.2K 0.05% 277
2024
Q2 		$1.29M Buy
51,029
+555
+1% +$15.2K 0.05% 254
2024
Q1 		$1.56M Buy
50,474
+4,127
+9% +$140K 0.06% 214
2023
Q4 		$1.87M Sell
46,347
-7,522
-14% -$226K 0.08% 187
2023
Q3 		$1.42M Sell
53,869
-40,596
-43% -$1.15M 0.08% 201
2023
Q2 		$1.62M Buy
94,465
+43,692
+86% +$657K 0.09% 185
2023
Q1 		$842K Buy
+50,773
New +$592K 0.05% 346
2022
Q3 		– Sell
-14,549
Closed -$132K – 928
2022
Q2 		$132K Sell
14,549
-1,974
-12% -$16.5K 0.01% 957
2022
Q1 		$168K Sell
16,523
-1,839
-10% -$18.9K 0.01% 1292
2021
Q4 		$306K Sell
18,362
-2,517
-12% -$106K 0.01% 968
2021
Q3 		$979K Buy
+20,879
New +$1.12M 0.03% 363

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Profund Advisors's BBIO Position: Q2 2026 in Review

Profund Advisors reduced its BridgeBio Pharma (BBIO) stake by 34% in Q2 2026, selling an estimated $732K and leaving 19,929 shares worth $1.48M. The position accounts for 0.04% of the portfolio, ranked #269.

Profund Advisors first reported a position in BBIO in Q3 2021 and has held it in 18 quarters since. The position peaked at $2.44M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Profund Advisors held 19,929 shares of BridgeBio Pharma worth $1.48M as of Q2 2026.
  • Profund Advisors sold 10,448 BridgeBio Pharma shares in Q2 2026, an estimated $732K.
  • BridgeBio Pharma made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #269 holding.
  • Profund Advisors first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 18 quarters since.
  • Profund Advisors's BridgeBio Pharma position peaked at $2.44M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.